American Thoracic Society (ATS) 2021

Reductions in asthma exacerbation-related hospitalizations and emergency department visits in patients with severe, uncontrolled asthma treated with tezepelumab: results from the phase 3 NAVIGATOR study

Efficacy of tezepelumab in patients with severe, uncontrolled asthma grouped according to combined baseline blood eosinophil count and fractional exhaled nitric oxide level: results from the NAVIGATOR phase 3 study

Effect of tezepelumab in oral corticosteroid-dependent patients with severe asthma: results from the phase 3 NAVIGATOR study

Reductions in inflammatory biomarkers in patients with oral corticosteroid-dependent asthma treated with tezepelumab

Oral corticosteroid-sparing effect of tezepelumab in patients with severe asthma

Effect of tezepelumab on airway inflammation in patients with moderate-to-severe uncontrolled asthma: a phase 2, randomized, double-blind, placebo-controlled study (CASCADE)

Adrenal Insufficiency Is Not a Barrier to OCS Elimination in the PONENTE Study

OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study

Longitudinal Blood Eosinophil Counts and Eosinophilic Immune Dysfunction Among Placebo Patients with Severe Asthma from Phase 3 Benralizumab Studies

Eosinophil as a Biomarker of Severity and Clinically Important Asthma Outcomes in Benralizumab Phase III Studies

Integrated Safety and Efficacy Among Patients with Severe Asthma Receiving Benralizumab for Up to Five Years

Real-World Effectiveness of Benralizumab on Asthma Exacerbations: Results from the ZEPHYR 1 Study

Real-world Evidence of Reported Symptoms and Quality of Life Burden Associated with Chronic Rhinosinusitis with Nasal Polyposis Across Disease Severity and Region

Clinical Effectiveness of Benralizumab Is Independent of Baseline FeNO in Severe Eosinophilic Asthma: A Retrospective Real-World Observation Study in Five UK Severe Asthma Centers

CT Mucus Score Predicts Benralizumab Response in Severe Asthma

Response to Benralizumab in Severe Asthma: Oscillometry and MRI Ventilation Defect Improvements in Participants with Abnormal FeNO

Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Patients with Moderate Chronic Obstructive Pulmonary Disease in the ETHOS Study

Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Patients with COPD by Baseline CAT Score: Post-Hoc Analysis of the ETHOS Study

Relationship Between Prior Inhaled Corticosteroid Use and Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate on Exacerbation Risk in Patients with Chronic Obstructive Pulmonary Disease: Analysis from the ETHOS Study

Projections of Healthcare Resource Utilization and Costs Related to Exacerbations for Budesonide/Glycopyrrolate/Formoterol Fumarate Versus Dual Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist and Inhaled Corticosteroid/Long-Acting β2‑Agonist Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease

Lifetime Benefits for Budesonide/Glycopyrrolate/Formoterol Fumarate versus Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist and Inhaled Corticosteroid/Long-Acting β2-Agonist Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease

Safety and Efficacy of Budesonide-Glycopyrrolate-Formoterol Fumarate for COPD in Black or African-American Patients: A Post-Hoc Subgroup Analysis of the ETHOS Study

Five-Year Real-World Cost Projections from SHERLOCK Based on Patient Profiles from the ETHOS Study

Prediction of 5 Year Severe Exacerbation and Mortality Risk by Baseline Exacerbation Status in the US- Application of the ETHOS Trial to a Real-World Analysis of COPD Patientsv

Pneumonia Burden and Exacerbations: A Large Real-World Evaluation of Events and Risks Among Chronic Obstructive Pulmonary Disease (COPD) Patients in the United States

Does Baseline Exacerbation History in COPD Predict Future Exacerbation Frequency? Real World Insights from Multiple US Insurers

PT010 Treatment Ameliorates Chronic Obstructive Pulmonary Disease and Subsequent Development of Pulmonary Hypertension

Overprescription of Short-Acting Beta2-Agonists in Asthma Patients from 6 Latin American Countries: Results from the SABINA International Study

Phase III Evaluation of the Efficacy and Safety of PT027 (Budesonide/Albuterol pMDI) Compared to Placebo pMDI on Exercise-Induced Bronchoconstriction in Adult and Adolescent Subjects with Asthma: the TYREE Study

Relationship of Annual Short-Acting Beta2-Agonist Use and Systemic Corticosteroid Exposure in Children and Adults with Asthma in the United States

Therapeutic and Management Preferences and Goals of Adults with Asthma: A Discrete Choice Experiment

Effect of Socioeconomic, Demographic and Clinical Factors on Asthma Treatment Preferences: A Discrete Choice Experiment

Results of a Phase 2b Dose Finding Study of Velsecorat, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator in Asthma (GRANIT)

Velsecorat (AZD7594), a Selective Glucocorticoid Receptor Modulator (SGRM) Demonstrates Favorable Pre-Clinical Efficacy vs Safety Profile Compared to Current Clinical Inhaled Steroid, Fluticasone Furoate

Results and Learnings from AMBER, a Decentralized Phase I Study Assessing the Pharmacokinetic and Pharmacodynamic Profile of Inhaled Velsecorat, a Non-Steroidal, Selective Glucocorticoid Receptor Modulator, in Adolescents with Asthma

Real-Time Clinical Assessment and Temporal Predictions of CompEx Events

Factors Predictive of Exacerbations and Asthma Hospitalizations Among Patients with Specialist-Confirmed Severe Asthma in the United States

Demographic Characteristics and Laboratory Biomarker Testing of Patients Receiving Individual Biologic Therapies for Severe Asthma in the United States

Impact of COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Specialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study

Worldwide Characterization of Severe Asthma Patients Eligible for Both Anti-IL5 and Anti-IgE: Data from the International Severe Asthma Registry (ISAR)

Evaluating Performance of the Asthma Impairment and Risk Questionnaire (AIRQ™) in Primary and Specialty Care

Patterns of Care and Factors Associated with Care Specialty in Individuals with Asthma Who Required Hospitalization: A Retrospective Population-Based Study

Validation of the Chronic Airways Assessment Test in the NOVELTY Study

Impact of the UK Lockdown on Early COPD

A Novel Mechanism of Action for the NK1 Receptor in Airway Sensory Nerves

Activation of GPR35 Inhibits Airway Sensory Nerves and the Late Asthmatic Response in Preclinical Model Systems

Identification of Subjects with High Risk of Disease Progression Using Data from the COPDGene Cohort

Inhibition of NLRP3 Inflammasome Reduces the Intracellular Survival of Non-Typeable Haemophilus Influenzae Isolated from Patients with COPD

PI3Kγd Inhibitor, AZD8154, Demonstrates Improved Efficacious Profile Over PI3Kd Selective Inhibitor, GSK2269557, in a Rat Model of Asthma

Preclinical In Vitro Differentiation of FLAP Inhibitors vs Montelukast and ICS

Extracellular Specks, a Marker of NLRP3 Inflammasome Activation

Novel Pharmacodynamic Model to Profile Inhibitors of NLRP3 in the Mouse Lung